Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Telehealth based virtual consult visits and in-person consult visits provide comparable time to HLA-typing and preliminary donor search in patients referred for allogeneic hematopoietic cell transplantation

Won Sung Kim, Kelli Goslee, Chelsea Bowman et al. Nov 03, 2025 pp. 1083-1083 10.1182/blood-2025-1083

Abstract Introduction: Allogeneic hematopoietic cell transplantation (alloHCT) is the only curative therapy for patients with high-risk hema...

Prednisolone and mycophenolate mofetil as first-line therapy in warm autoimmune hemolytic anemia: A prospective pilot study

Manthan Ghosh, Aditya Jandial, Charanpreet Singh et al. Nov 03, 2025 pp. 4669-4669 10.1182/blood-2025-4669

Abstract Background: Warm autoimmune hemolytic anemia (wAIHA) is a rare immune disorder characterised by autoantibody-mediated destruction o...

CRISPR/Cas9-mediated CISH deletion and CD16a upregulation potentiates ADCC in NK cells against relapsed/refractory multiple myeloma

Dana Samardali, Yashaswi Guntupalli, Sri Sai Githa Peri et al. Nov 03, 2025 pp. 7648-7648 10.1182/blood-2025-7648

Abstract Background Relapsed/refractory multiple myeloma (RRMM) remains incurable for many patients despite recent advances in proteasome in...

In Vivo clonal dynamics of alloreactive CAR T cells reveal mechanisms limiting gvhd risk following allogeneic CAR T cell therapy

Gabriele Inchingolo, Jennifer Brudno, James Kochenderfer et al. Nov 03, 2025 pp. 105-105 10.1182/blood-2025-105

Abstract Introduction: Allogeneic CAR T cell therapy holds curative potential for patients with relapsed or refractory B-cell malignancies t...

Reproductive health in patients with primary immune thrombocytopenia (ITP) receiving rilzabrutinib: A subgroup analysis from the Phase 3 LUNA3 multicenter study

Michele Lambert, Nicola Cooper, Maria Cristina Pascual Izquierdo et al. Nov 03, 2025 pp. 3027-3027 10.1182/blood-2025-3027

Abstract Introduction: ITP is an immune-mediated disorder characterized by low platelet counts with consequent increased bleeding risk. Addi...

Optimizing processes for adverse event management for bispecific antibodies for diffuse large b-cell lymphoma in community practice: Insights from a quality improvement initiative

Krish Patel, Joshua Brody, M. Sarfraz Nawaz et al. Nov 03, 2025 pp. 6183-6183 10.1182/blood-2025-6183

Abstract Background In a previous quality improvement (QI) study designed to assess and address barriers to the adoption of novel therapies...

PARP1 inhibition sensitizes AML to CD123 CAR-NK cells via immunophenotypic remodeling

Lea Kramer, Saskia Rudat, Shalini Ramachandran et al. Nov 03, 2025 pp. 2357-2357 10.1182/blood-2025-2357

Abstract Background:Acute myeloid leukemia (AML) is an aggressive hematologic malignancy driven by leukemic stem cells (LSCs) with enhanced...

Real world outcomes of patients with CML-CP treated with tyrosine kinase inhibitors from the h. jean khoury cure CML consortium (HJKC3)

Ehab Atallah, Emily Giever, Jorge Cortés et al. Nov 03, 2025 pp. 2844-2844 10.1182/blood-2025-2844

Abstract Background: The H. Jean Khoury Cure CML Consortium (HJKC3) was established with the overarching goals of improving the outcomes for...

Real-world safety and efficacy of aponermin and selinexor-based regimens in patients with multiple myeloma

Xiaozhe Li, Chengcheng Fu, Chunrui Li et al. Nov 03, 2025 pp. 7588-7588 10.1182/blood-2025-7588

Abstract Background: Treatment of relapsed/refractory multiple myeloma (RRMM) and frail newly diagnosed multiple myeloma (NDMM) patients rem...

An acquired immune-metabolic shift to common chemotherapy confers resistance to immunotherapies in relapsed, high-risk multiple myeloma

Mara John, Nazia Afrin, Emilia Stanojkovska et al. Nov 03, 2025 pp. 3938-3938 10.1182/blood-2025-3938

Abstract Introduction: The prognosis of multiple myeloma (MM) has improved significantly with the advent of targeted agents and immunotherapi...

Hematologic toxicities associated with PARP inhibitors: Real world pharmacovigilance updated study using faers database with era-trend evaluation and serious outcome modeling

Rushi Shah, Sai Sushrutha Mudupula Vemula, Nikhil Kumar Kotla et al. Nov 03, 2025 pp. 4474-4474 10.1182/blood-2025-4474

Abstract Background: Poly ADP-ribose polymerase inhibitors (PARPi) have improved outcomes in cancers, particularly ovarian and breast cancer...

Umbilical cord blood microtransplantation improves the prognosis of patients with relapsed/refractory myeloid tumors who are not candidates for intensive therapy: Clinical efficacy and mechanism analysis

Chenxiao Du, Shiqin Luo, Yuhui Zhang et al. Nov 03, 2025 pp. 7656-7656 10.1182/blood-2025-7656

Abstract Objective: There is no unified standard for the optimal treatment of relapsed/refractory acute myeloid tumors (R/R MN). At present,...

Identification of two distinct human hematopoietic stem cell subsets and their age-dependent dynamics by single-cell multi-omics

Xinjian Mao, Ning Zhang, Xi He et al. Nov 03, 2025 pp. 4943-4943 10.1182/blood-2025-4943

Abstract Hematopoietic stem cells (HSCs) sustain lifelong blood production due to their unique capacities for self-renewal and multilineage...

Long-term HIV remission of a perinatally infected individual, following a hematopoietic cell transplantation from a CCR5Δ32 homozygous donor for multiple myeloma: The kyiv patient

Sybiryna Korenkova, Bogdan Medvedev, Arnold Ganser et al. Nov 03, 2025 pp. 7800-7800 10.1182/blood-2025-7800

Abstract Introduction: Antiretroviral therapy (ART) suppresses replication of HIV, though its inability to clear the latently infected reser...

The impact of viral pneumonia on hospital outcomes in sickle cell disease: A database review and analysis

Kaung Htet Hla Win, Samuel Sule-Saa, Muhanned Faisal Towfig et al. Nov 03, 2025 pp. 1196-1196 10.1182/blood-2025-1196

Abstract Introduction: Sickle cell disease (SCD) is a subset of hereditary hemoglobinopathies characterized by chronic hemolysis, vaso-occlu...

Abatacept in combination with post-transplant cyclophosphamide and tacrolimus may improve survival and non-relapse mortality without increasing relapse risk after allogeneic stem cell transplantation

Yasser Khaled, Samer Khaled, Juan Varela et al. Nov 03, 2025 pp. 4218-4218 10.1182/blood-2025-4218

Abstract Introduction: Recent studies have shown the safety and feasibility of abatacept (ABA) addition to post-transpla...

Number of patients needed to treat to prevent one atrial fibrillation event with zanubrutinib versus ibrutinib and acalabrutinib in B-cell malignancies

Talha Munir, Paolo Sportoletti, Leyla Mohseninejad et al. Nov 03, 2025 pp. 8024-8024 10.1182/blood-2025-8024

Abstract Introduction Bruton tyrosine kinase inhibitors (BTKis) are used for the treatment of B-cell malignancies. Second generation (acalab...

Synergistic enhancement of γδ T cell cytotoxicity against tumor spheroids through B7H3 CAR and zoledronate sensitization

Aylin Sassor, Nayana Nambiar, Rimas Orentas et al. Nov 03, 2025 pp. 7634-7634 10.1182/blood-2025-7634

Abstract Despite significant progress in treating hematological malignancies with chimeric antigen receptor (CAR) T cell therapies, their ap...

Identifying and overcoming mechanisms of resistance to a VpreB1-directed antibody-drug conjugate in the treatment of B-cell acute lymphoblastic leukemia

Robin Williams, Xiaohong Wang, Jason Ostergaard et al. Nov 03, 2025 pp. 5115-5115 10.1182/blood-2025-5115

Abstract Background: The treatment landscape of B-cell acute lymphoblastic leukemia (B-ALL) has been transformed by ther...

Lamin B1 mediates dynamic changes in heterochromatin and regulates erythropoiesis

Dawei Huo, Rui Wen, Qiqi Zhang et al. Nov 03, 2025 pp. 2885-2885 10.1182/blood-2025-2885

Abstract Chromatin condensation is a crucial step in the maturation process of red blood cells. we explored the distribution changes of chro...

Single-center retrospective analysis of venetoclax-based triple-drug combination therapy for relapsed Acute Myeloid Leukemia  post allogeneic hematopoietic stem cell transplantation.

Xi Yang, Cheng Li, Yu Wang et al. Nov 03, 2025 pp. 7808-7808 10.1182/blood-2025-7808

Abstract Objective: To evaluate the efficacy and safety of venetoclax (VEN), cytarabine, and azacitidine (AZA) combination therapy in relaps...

Immune checkpoint inhibitor–associated cytopenias: A decade of real-world signal detection from faers (2014–2025)

Manzer Ali, Kashish Magnani, Saad Rashid et al. Nov 03, 2025 pp. 6255-6255 10.1182/blood-2025-6255

Abstract Background: Immune checkpoint inhibitors (ICIs) targeting PD-1, PD-L1, and CTLA-4 have transformed cancer therapy. However, their e...

Characterization of two genetically distinct subtypes of C5 diffuse large B-cell lymphoma (DLBCL)

Meng Wang, Joji Shimono, Shashwat Sahay et al. Nov 03, 2025 pp. 50-50 10.1182/blood-2025-50

Abstract Diffuse large B-cell lymphoma (DLBCL) is a clinically and molecularly heterogeneous disease with two recognized transcriptional sub...

Non-GCB cell of origin leads to inferior outcomes in brazilian diffuse large B-cell lymphoma patients: Bra-DLBCL multicenter registry, retrospective study of over 500 patients

Guilherme Perini, Larissa Teixeira, Carolina Feres et al. Nov 03, 2025 pp. 6323-6323 10.1182/blood-2025-6323

Abstract Introduction Despite the improvement in management of diffuse large B-cell lymphoma (DLBCL) in recent years, th...

An open-label, Phase I/II clinical trial of romaciclib (RVU120) as monotherapy and in combination with ruxolitinib in patients with intermediate or high-risk, primary or secondary myelofibrosis (POTAMI-61)

Tomasz Sacha, Marcin Rymko, Katarzyna Dulik et al. Nov 03, 2025 pp. 2045-2045 10.1182/blood-2025-2045

Abstract Background Myelofibrosis (MF) is associated with dysregulated JAK1/2 signaling. Ruxolitinib (RUX, JAK1/2 inhibitor) was the first t...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page